secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001104659-23-067030
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune completes all-stock combination with TCR2; creates solid tumor cell therapy leader
--------------------------------------------------------------------------------

- Merger closed June 1, 2023; Adaptimmune shareholders own ~75%, former TCR2 stockholders own ~25% of combined company.
- BLA for afami-cel (synovial sarcoma) on track for mid-2023; 70% of responders alive at 2 years in SPEARHEAD-1 trial.
- New directors appointed: Andrew Allen, Priti Hegde, Garry Menzel (ex-TCR2); Barbara Duncan and James Noble resigned.
- Combined pipeline targets MAGE-A4, mesothelin, PRAME, CD70; company funded into early 2026.
- Dr. Garry Menzel receives separation: $1.28M severance (18 months), $343,750 bonus, $171,875 transaction bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/tm2317177d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-067030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer